Cookies on this website

We use cookies to ensure that we give you the best experience on our website. If you click 'Accept all cookies' we'll assume that you are happy to receive all cookies and you won't see this message again. If you click 'Reject all non-essential cookies' only necessary cookies providing core functionality such as security, network management, and accessibility will be enabled. Click 'Find out more' for information on how to change your cookie settings.

Dr Parinaz Mehdipour

Research in our lab focuses on assessing basic and translational aspects of epigenetic regulation and RNA modifications in the treatment of cancer. We investigate how the mammalian innate immune system can discriminate between endogenous and exogenous nucleic acids, such as from viruses. For example, we and others have shown that treating cancer cells with DNA methylation inhibitors can trigger production of double-stranded RNAs (dsRNAs) from repetitive sequences, mimicking viral infection. We are particularly interested in exploring immunogenic dsRNAs as biomarkers for predicting and monitoring the responses to cancer treatment.

Key aims of our research group:

  • To study the translational role of immunogenic dsRNAs as biomarkers for predicting and monitoring the response of cancer cells to cancer therapies.
  • To understand the mechanisms by which the mammalian innate immune system discriminates endogenous from exogenous nucleic acids and exploit this to improve the cancer treatment.
  • To identify novel candidates for therapeutic targeting in cancer.

Find out more about research in the Mehdipour group

Our team